Hyperlipoproteinemia Type II
"Hyperlipoproteinemia Type II" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A group of familial disorders characterized by elevated circulating cholesterol contained in either LOW-DENSITY LIPOPROTEINS alone or also in VERY-LOW-DENSITY LIPOPROTEINS (pre-beta lipoproteins).
| Descriptor ID |
D006938
|
| MeSH Number(s) |
C16.320.565.398.481 C18.452.584.500.500.644.475 C18.452.648.398.481
|
| Concept/Terms |
Hyperlipoproteinemia Type II- Hyperlipoproteinemia Type II
- Hyperlipoproteinemia Type IIs
- Hyper-Low Density Lipoproteinemia
- Density Lipoproteinemia, Hyper-Low
- Density Lipoproteinemias, Hyper-Low
- Hyper Low Density Lipoproteinemia
- Hyper-Low Density Lipoproteinemias
- Lipoproteinemia, Hyper-Low Density
- Lipoproteinemias, Hyper-Low Density
- Hyper-Low-Density-Lipoproteinemia
- Hyper-Low-Density-Lipoproteinemias
- Hyperlipoproteinemia, Type II
- Hyperlipoproteinemias, Type II
- Type II Hyperlipoproteinemia
- Type II Hyperlipoproteinemias
- Hypercholesterolemia, Essential
- Essential Hypercholesterolemia
- Essential Hypercholesterolemias
- Hypercholesterolemias, Essential
- Hypercholesterolemia, Familial
- Familial Hypercholesterolemia
- Familial Hypercholesterolemias
- Hypercholesterolemias, Familial
- Hypercholesterolemic Xanthomatosis, Familial
- Familial Hypercholesterolemic Xanthomatoses
- Familial Hypercholesterolemic Xanthomatosis
- Hypercholesterolemic Xanthomatoses, Familial
- Xanthomatoses, Familial Hypercholesterolemic
- Xanthomatosis, Familial Hypercholesterolemic
- Hyperlipoproteinemia Type 2
- Hyperlipoproteinemia Type 2s
- Type 2, Hyperlipoproteinemia
- Hyper-beta-Lipoproteinemia
- Hyper beta Lipoproteinemia
- Hyper-beta-Lipoproteinemias
- Hyperbetalipoproteinemia
- Hyperbetalipoproteinemias
Hyperlipoproteinemia Type IIb- Hyperlipoproteinemia Type IIb
- Hyperlipoproteinemia Type IIbs
- Hypercholesterolemia, Autosomal Dominant, Type B
- Familial Combined Hyperlipoproteinemia
- Combined Hyperlipoproteinemia, Familial
- Combined Hyperlipoproteinemias, Familial
- Familial Combined Hyperlipoproteinemias
- Hyperlipoproteinemia, Familial Combined
- Hyperlipoproteinemias, Familial Combined
- Apolipoprotein B-100, Familial Defective
- Apolipoprotein B 100, Familial Defective
- Apolipoprotein B-100, Familial Ligand-Defective
- Apolipoprotein B 100, Familial Ligand Defective
Hyperlipoproteinemia Type IIa- Hyperlipoproteinemia Type IIa
- Hyperlipoproteinemia Type IIas
- Hyperlipoproteinemia, Type IIa
- Hyperlipoproteinemias, Type IIa
- Type IIa Hyperlipoproteinemia
- Type IIa Hyperlipoproteinemias
- Hypercholesterolemia, Autosomal Dominant
- Autosomal Dominant Hypercholesterolemia
- Autosomal Dominant Hypercholesterolemias
- Dominant Hypercholesterolemia, Autosomal
- Dominant Hypercholesterolemias, Autosomal
- Hypercholesterolemias, Autosomal Dominant
- LDL Receptor Disorder
- Disorder, LDL Receptor
- Disorders, LDL Receptor
- LDL Receptor Disorders
- Receptor Disorder, LDL
- Receptor Disorders, LDL
|
Below are MeSH descriptors whose meaning is more general than "Hyperlipoproteinemia Type II".
Below are MeSH descriptors whose meaning is more specific than "Hyperlipoproteinemia Type II".
This graph shows the total number of publications written about "Hyperlipoproteinemia Type II" by people in this website by year, and whether "Hyperlipoproteinemia Type II" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 1 | 1 | 2 |
| 2019 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hyperlipoproteinemia Type II" by people in Profiles.
-
Torres E, Goicoechea M, Hern?ndez A, Rodr?guez Ferrero ML, Garc?a A, Mac?as N, Anaya F. Efficacy of Evolocumab vs low-density lipoprotein cholesterol apheresis in patients with familial hypercholesterolemia and high cardiovascular risk (EVOLAFER01). J Clin Apher. 2020 Jan; 35(1):9-17.
-
Khera AV, Won HH, Peloso GM, Lawson KS, Bartz TM, Deng X, van Leeuwen EM, Natarajan P, Emdin CA, Bick AG, Morrison AC, Brody JA, Gupta N, Nomura A, Kessler T, Duga S, Bis JC, van Duijn CM, Cupples LA, Psaty B, Rader DJ, Danesh J, Schunkert H, McPherson R, Farrall M, Watkins H, Lander E, Wilson JG, Correa A, Boerwinkle E, Merlini PA, Ardissino D, Saleheen D, Gabriel S, Kathiresan S. Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia. J Am Coll Cardiol. 2016 06 07; 67(22):2578-89.
-
Guo Y, Fan Y, Zhang J, Lomberk GA, Zhou Z, Sun L, Mathison AJ, Garcia-Barrio MT, Zhang J, Zeng L, Li L, Pennathur S, Willer CJ, Rader DJ, Urrutia R, Chen YE. Perhexiline activates KLF14 and reduces atherosclerosis by modulating ApoA-I production. J Clin Invest. 2015 Oct 01; 125(10):3819-30.
-
Yang H, Roberts LJ, Shi MJ, Zhou LC, Ballard BR, Richardson A, Guo ZM. Retardation of atherosclerosis by overexpression of catalase or both Cu/Zn-superoxide dismutase and catalase in mice lacking apolipoprotein E. Circ Res. 2004 Nov 26; 95(11):1075-81.
-
Aliev G, Castellani RJ, Petersen RB, Burnstock G, Perry G, Smith MA. Pathobiology of familial hypercholesterolemic atherosclerosis. J Submicrosc Cytol Pathol. 2004 Jul-Oct; 36(3-4):225-40.